Marijuana Use and Cardiovascular Risks: What the Latest Research Shows
A recent analysis published in the article in the Journal of the American College of Cardiology estimates that more than two million U.S. adults living with cardiovascular disease have used marijuana.
The study combined a review of existing evidence with data from the National Health and Nutrition Examination Survey (NHANES) collected between 2015 and 2016. Of the roughly 89.6 million adults who reported ever using marijuana, about 2 million also reported a diagnosis of congestive heart failure, coronary heart disease, or a prior heart attack.
Lead author Ersilia M. DeFilippis, MD, a cardiology fellow at Columbia University Irving Medical Center, notes that the figure is striking and that marijuana use has risen since the survey period.
She also points out that many individuals may be at risk for heart disease without a formal diagnosis, underscoring the need for better data on this intersection.
What the Evidence Says About Marijuana and Heart Health
Epidemiological studies have linked cannabis use to several cardiovascular concerns, including arrhythmias, cardiomyopathy, myocardial infarction, and stroke. A meta‑analysis cited in the review identified smoking marijuana as one of the top three precipitating factors for heart attack. In a separate study of 334 stroke patients under the age of 45, 17 % tested positive for cannabis.
Although the active compounds in cannabis differ from those in tobacco, the smoke produced contains roughly 4,000 chemicals that are largely identical to those found in tobacco smoke, according to a 2003 BMJ comparison.
Given that tobacco smoking is a well‑established risk factor for cardiovascular disease, the similarity raises important questions about how inhaled marijuana may affect the heart and how clinicians should counsel patients.
Potential Interactions With Cardiac Medications
The review also highlights pharmacokinetic interactions between marijuana and common heart medications. For example, statins—used to lower cholesterol—can reach higher blood concentrations when taken alongside cannabis because of shared metabolic pathways. Similar elevations have been observed for blood thinners and beta‑blockers, which are prescribed to prevent stroke and manage blood pressure.
Because the chemical profile of marijuana varies widely between strains, these interactions can be unpredictable, reinforcing the need for clinicians to ask patients about cannabis use when managing cardiovascular therapies.
Moving Toward Better Guidance
With cardiovascular disease remaining the leading cause of death in the United States, DeFilippis advises anyone with—or at risk for—heart disease to discuss marijuana use with their healthcare provider, whether the use is recreational or medically prescribed.
She hopes that future controlled studies will clarify the risks and enable evidence‑based guidelines for physicians and pharmacists alike.
This article first appeared on The Journalist’s Resource and is republished here under a Creative Commons Attribution-NoDerivatives 4.0 International License.
For the original source, see Here
